Volume 32, Issue 1 (April 2021)
Studies in Medical Sciences 2021, 32(1): 23-31 |
Back to browse issues page
Mahtab Bazdar 
, Farid Javandoust Gharehbagh , تقی زاده افشاری Taghizadeh Afshari , Mohammad Hasan Khadem Ansari , Jaffar Nouroozzadeh *
, Farid Javandoust Gharehbagh , تقی زاده افشاری Taghizadeh Afshari , Mohammad Hasan Khadem Ansari , Jaffar Nouroozzadeh *
Nephrology and Kidney Transplant Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran (Corresponding author) , jnouroozzadeh@yahoo.co.uk
Abstract: (2015 Views)
Background & Aims: Early detection of allograft dysfunction is important for the evaluation of postoperative outcome. The aim of this study was to evaluate the trend of changes in serum Creatinine (sCr) and Beta2-microglobulin (B2M) in kidney recipients (KRs) from living donors.
Materials & Methods: Blood samples were collected from KRs (n=39) at eight checkpoints starting at the day before transplantation. Based on serum creatinine (sCr; mg / dl) on the fifth day after transplantation (i.e. <1.70 or > 1.70), the KRs were classified into Good Early Graft Function (GEGF) and Poor Early Graft Function (PEGF) groups. Demographic and clinical indicators of the recipients were extracted from hospital database. The sCr was measured by Jaffe's and serum sB2M was measured by ELISA methods. The statistical population was described using the median index. The difference between the two groups was evaluated with a significance level of 0.05 and the Independent T-test and relevant graphs were drawn with Excel 2016.
Results: The distribution of GEGF and PEGF was 66.7% and 33.3%, respectively. In the GEGF, the sCr levels gradually decreased reaching a nadir at 36 hours after the surgery. In the PEGE, the slope for sCr elimination was slower than that of the GEGF patients. In the case of sB2M, the trend for GEGF patients reached a nadir at 72 hours after the surgery. For the PEGF group, no changes were recorded for B2M during the follow-up.
Conclusion: The present study is the first to explore the diagnostic value of serum B2M in KRs from living donors. This pilot study shows that B2M is capable of identifying KRs at high risk for reduced renal function. Further studies are required to evaluate the diagnostic performance of as biomarker of allograft dysfunction.
Materials & Methods: Blood samples were collected from KRs (n=39) at eight checkpoints starting at the day before transplantation. Based on serum creatinine (sCr; mg / dl) on the fifth day after transplantation (i.e. <1.70 or > 1.70), the KRs were classified into Good Early Graft Function (GEGF) and Poor Early Graft Function (PEGF) groups. Demographic and clinical indicators of the recipients were extracted from hospital database. The sCr was measured by Jaffe's and serum sB2M was measured by ELISA methods. The statistical population was described using the median index. The difference between the two groups was evaluated with a significance level of 0.05 and the Independent T-test and relevant graphs were drawn with Excel 2016.
Results: The distribution of GEGF and PEGF was 66.7% and 33.3%, respectively. In the GEGF, the sCr levels gradually decreased reaching a nadir at 36 hours after the surgery. In the PEGE, the slope for sCr elimination was slower than that of the GEGF patients. In the case of sB2M, the trend for GEGF patients reached a nadir at 72 hours after the surgery. For the PEGF group, no changes were recorded for B2M during the follow-up.
Conclusion: The present study is the first to explore the diagnostic value of serum B2M in KRs from living donors. This pilot study shows that B2M is capable of identifying KRs at high risk for reduced renal function. Further studies are required to evaluate the diagnostic performance of as biomarker of allograft dysfunction.
Keywords: Serum Beta2-microglobulin, Creatinine, Kidney transplantation, Good Early Graft Function, Poor Early Graft Function
References
1. Woo YM, Jardine AG, Clark AF, Macgregor MS, Bowman AW, Macpherson SG, et al. Early graft function and patient survival following cadaveric renal transplantation. Kidney Int 1999;55(2):692-9. [DOI:10.1046/j.1523-1755.1999.00294.x] [PMID]
2. Crews DC, Bello AK, Saadi G. 2019 World Kidney Day Editorial-burden, access, and disparities in kidney disease. Brazilian Journal of Nephrology. J Bras Nefrol 2019;41(1):1-9. [DOI:10.1590/2175-8239-jbn-2018-0224] [PMID] [PMCID]
3. Nephrology and Kidney Transplant Research Center [Internet]. 2014 [cited 2021 May 2]. Available from: https://nkt.umsu.ac.ir/index.aspx?fkeyid=&siteid=76&pageid=13128. [URL]
4. Nel D, Vogel J, Muller E, Barday Z, Kahn D. Slow early graft function: a neglected entity after renal transplantation. Nephron Clin Pract 2012;120(4):c200-c4. [DOI:10.1159/000340032] [PMID]
5. Malyszko J, Lukaszyk E, Glowinska I, Durlik M. Biomarkers of delayed graft function as a form of acute kidney injury in kidney transplantation. Sci Rep 2015;5:11684. [DOI:10.1038/srep11684] [PMID] [PMCID]
6. Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. Jama 2011;305(15):1545-52. [DOI:10.1001/jama.2011.468] [PMID] [PMCID]
7. Waikar SS, Betensky RA, Bonventre JV. Creatinine as the gold standard for kidney injury biomarker studies? Nephrol Dial Transplant 2009;24(11):3263-5.8. Winchester JF, Salsberg JA, Levin NW. Beta-2 microglobulin in ESRD: an in-depth review. Adv Ren Replace Ther 2003;10(4):279-309. [DOI:10.1053/j.arrt.2003.11.003] [PMID]
8. Yamamoto S, Gejyo F. Historical background and clinical treatment of dialysis-related amyloidosis. Biochim Biophys Acta;1753(1):4-10. [DOI:10.1016/j.bbapap.2005.09.006] [PMID]
9. Bernier GM, Conrad ME. Catabolsm of human beta-2-microglobulin by the rat kidney. Am J Physiol1969;217(5):1359-62. [DOI:10.1152/ajplegacy.1969.217.5.1359] [PMID]
10. Sonkar G, Singh R. A preliminary study on the significant value of beta-2-microglobulin over serum creatinine in renal transplant rejection and renal failure. Singapore Med J2008;49(10):786. [Google Scholar]
11. Liu P, Djamali A, Kaufman D, Astor B, editors. Post-Transplant Changes in Serum Creatinine and Beta-2 Microglobulin Predict Acute Tubular Necrosis in the Early Post-Transplant Period. Am J Transplant 2015; 15 (suppl 3). [URL]
12. Mir Ahmadian M, Nikbin B, Rezai A. Serum beta-2-Microglobulin level: A parameter for early diagnosis of renal allograft rejection. Tehran Univ Med J 1994;52(3):1-12. [Google Scholar]
13. Mahdavi-Mazdeh M, Amerian M, Abdollahi A, Hatmi Z, Khatami M. Comparison of serum neutrophil gelatinase-associated lipocalin (NGAL) with serum creatinine in prediction of kidney recovery after renal transplantation. Int J Organ Transplant Med 2012;3(4):176. [DOI:10.1097/00007890-201211271-02029]
14. Salamzadeh J, Sahraee Z, Nafar M, Parvin M. Delayed graft function (DGF) after living donor kidney transplantation: a study of possible explanatory factors. Ann Transplant 2012;17(3):69-76. [DOI:10.12659/AOT.883460] [PMID]
15. Mojtahedzadeh M, Etezadi F, Motaharinia J, Abrandabadi AHN. Predictive values of urinary interleukin 18 and neutrophil gelatinase-associated lipocalin for delayed graft function diagnosis in kidney transplantation. Iran J pathol 2016;11(4):391. [Google Scholar]
16. Yokoyama I, Uchida K, Kobayashi T, Tominaga Y, Orihara A, Takagi H. Effect of prolonged delayed graft function on long-term graft outcome in cadaveric kidney transplantation. Clin Transplant 1994;8(2 Pt 1):101-6. [Google Scholar]
17. Matas AJ, Tellis VA, Quinn TA, Glicklich D, Soberman R, Veith FJ. Timing of cyclosporine administration in patients with delayed graft function. J Surg Res 1987;43(6):489-94. [DOI:10.1016/0022-4804(87)90121-1]
18. Almond P, Troppmann C, Escobar F, Frey D, Matas AJ. Economic impact of delayed graft function. Transplant Proc 1991;23(1 Pt 2):1304. [URL]
19. Benvenisty AI, Cohen D, Stegall MD, Hardy MA. Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function. Transplantation 1990;49(2):321-7. [DOI:10.1097/00007890-199002000-00019] [PMID]
20. Johnston O, O'Kelly P, Spencer S, Donohoe J, Walshe JJ, Little DM, et al. Reduced graft function (with or without dialysis) vs immediate graft function-a comparison of long-term renal allograft survival. Nephrol Dial Transplant 2006;21(8):2270-4. [DOI:10.1093/ndt/gfl103] [PMID]
21. Cui L-Y, Zhu X, Yang S, Zhou J-S, Zhang H-X, Liu L, et al.. Prognostic value of levels of urine neutrophil gelatinase-associated lipocalin and interleukin-18 in patients with delayed graft function after kidney transplantation. Transplant Proc 2015 Dec;47(10):2846-51. [DOI:10.1016/j.transproceed.2015.10.042] [PMID]
22. Hall IE, Doshi MD, Poggio ED, Parikh CR. A comparison of alternative serum biomarkers with creatinine for predicting allograft function after kidney transplantation. Transplantation 2011;91(1):48-56. [DOI:10.1097/TP.0b013e3181fc4b3a] [PMID]
23. Sedighi O, Abediankenari S, Omranifar B. Association between plasma Beta-2 microglobulin level and cardiac performance in patients with chronic kidney disease. Nephrourol Mon 2015;7(1) :e23563. [DOI:10.5812/numonthly.23563] [PMID] [PMCID]
24. Stanga Z, Nock S, Medina-Escobar P, Nydegger UE, Risch M, Risch L. Factors other than the glomerular filtration rate that determine the serum beta-2-microglobulin level. PloS one 2013;8(8):e72073. [DOI:10.1371/journal.pone.0072073] [PMID] [PMCID]
25. Trailin AV, Pleten MV, Ostapenko TI, Iefimenko NF, Nikonenko OS. High serum level of β2-microglobulin in late posttransplant period predicts subsequent decline in kidney allograft function: a preliminary study. Dis Markers 2015;2015:562580. [DOI:10.1155/2015/562580] [PMID] [PMCID]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |